MedTech

Biopharma firm SynOx secures $35m in debt funding

News comes just days after the late-stage biopharma company raises $75 in funding

TGCT is a type of tumour that affects the soft tissue lining of joints and tendons and is a highly debilitating disease. Picture: Getty

SynOx Therapeutics, a Dublin-headquartered late-stage clinical biopharmaceutical company, has secured $35 million in debt funding just days after raising $75 million from investors.

The company was founded in 2020 after securing worldwide rights to develop a drug candidate called Emactuzumab under a licence agreement with Roche.

Read our top subscriber stories

An Bord Pleanála concedes challenge to more than 850 homes in Dundrum

Red C poll: Independents rise again as Fianna Fáil slumps to two-year low

Guinness 0.0: Huge rise in sales cause Diageo to push for more taps

Exclusive: Trinity College faces threat of industrial action from thousands of staff

30 under 30: The bright young stars of Ireland’s tech scene